Indivior CEO pleads guilty to charge over opioid drug Suboxone

1 July 2020

Shaun Thaxter, the chief executive of Indivior (LSE: INDV), has pleaded guilty to causing the introduction into interstate commerce of the opioid drug Suboxone Film (buprenorphine) which was misbranded in violation of the Federal Food, Drug, and Cosmetic Act.

Mr Thaxter will be stepping down as chief executive of the firm, which prior to 2009 was known as Reckitt Benckiser Pharmaceuticals and was a subsidiary of Reckitt Benckiser Group, a British conglomerate that paid $1.4 billion in 2019 to resolve its liability to the USA and various states related to the marketing of Suboxone.

Indivior issued a statement stressing that Mr Thaxter’ guilty plea was in his personal capacity and not on behalf of the Group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK